Willem Buján

1.3k total citations · 1 hit paper
21 papers, 876 citations indexed

About

Willem Buján is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, Willem Buján has authored 21 papers receiving a total of 876 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Hematology, 8 papers in Genetics and 5 papers in Oncology. Recurrent topics in Willem Buján's work include Hemophilia Treatment and Research (4 papers), Lymphoma Diagnosis and Treatment (4 papers) and Neuroblastoma Research and Treatments (3 papers). Willem Buján is often cited by papers focused on Hemophilia Treatment and Research (4 papers), Lymphoma Diagnosis and Treatment (4 papers) and Neuroblastoma Research and Treatments (3 papers). Willem Buján collaborates with scholars based in Belgium, France and Costa Rica. Willem Buján's co-authors include Johnny Mahlangu, Claude Négrier, Elina Asikanius, Rebecca Kruse‐Jarres, Michael U. Callaghan, Johannes Oldenburg, Midori Shima, Markus Niggli, Christophe Dhalluin and Gallia G. Levy and has published in prestigious journals such as New England Journal of Medicine, Blood and PEDIATRICS.

In The Last Decade

Willem Buján

20 papers receiving 839 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors

2018 503 citations Johnny Mahlangu, Johannes Oldenburg et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Willem Buján

Since Specialization

Citations

This map shows the geographic impact of Willem Buján's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Willem Buján with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Willem Buján more than expected).

Fields of papers citing papers by Willem Buján

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Willem Buján. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Willem Buján. The network helps show where Willem Buján may publish in the future.

Co-authorship network of co-authors of Willem Buján

This figure shows the co-authorship network connecting the top 25 collaborators of Willem Buján. A scholar is included among the top collaborators of Willem Buján based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Willem Buján. Willem Buján is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The paradox of haematopoietic cell transplant in Latin America 2021 ·Bone Marrow Transplantation ·Gregorio Jaimovich, Robert Peter Gale, (unknown), (unknown), (unknown), Belinda Pinto Simões, (unknown), (unknown), David Gómez‐Almaguer, (unknown), (unknown), (unknown), Willem Buján, (unknown), (unknown), Amado Karduss, Sebastián Galeano, Juliana Martínez Rolón	7
2	Emicizumab Prophylaxis Administered Once-weekly or Every Two Weeks Provides Effective Bleed Prevention in Persons with Hemophilia A (PwHA) without Inhibitors - Results from the Phase III HAVEN 3 Study 2019 ·Hämostaseologie ·Johannes Oldenburg, Johnny Mahlangu, Ido Paz‐Priel, Claude Négrier, Markus Niggli, Maria Elisa Mancuso, Christophe Schmitt, Víctor Jiménez‐Yuste, Christine L. Kempton, Christophe Dhalluin, Michael U. Callaghan, Willem Buján, Midori Shima, Joanne I. Adamkewicz, Elina Asikanius, Gallia G. Levy, Rebecca Kruse‐Jarres	2
3	Emicizumab Prophylaxis Administered Once-weekly or Every Two Weeks Provides Effective Bleed Prevention in Persons with Hemophilia A (PwHA) without Inhibitors - Results from the Phase III HAVEN 3 Study 2019 ·Hämostaseologie ·Johannes Oldenburg, Johnny Mahlangu, (unknown), Claude Négrier, Markus Niggli, (unknown), Christophe Schmitt, Víctor Jiménez‐Yuste, Christine L. Kempton, Christophe Dhalluin, Michael U. Callaghan, Willem Buján, Midori Shima, (unknown), Elina Asikanius, (unknown), Rebecca Kruse‐Jarres	1
4	Significant Differences in Test Availability and Access to Novel Drugs for Multiple Myeloma between Public and Private Hospitals in Latin America. Grupo De Estudio Latinoamericano De Mieloma Multiple (GELAMM) 2018 ·Blood ·Eloísa Riva, (unknown), Camila Peña, (unknown), Guillermo J. Ruíz‐Argüelles, (unknown), Willem Buján, (unknown), Christine Rojas, (unknown), (unknown), (unknown), (unknown), Dorotea Fantl	3
5	The effect of emicizumab prophylaxis on health‐related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study 2018 ·Haemophilia ·Johannes Oldenburg, Johnny Mahlangu, Willem Buján, Peter C. Trask, Michael U. Callaghan, Guy Young, Elina Asikanius, Flora Peyvandi, Elena Santagostino, Rebecca Kruse‐Jarres, Claude Négrier, Craig M. Kessler, Jin Xu, Jerzy Windyga, Midori Shima, Sylvia von Mackensen	70
6	Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors breakdown → 2018 ·New England Journal of Medicine ·Johnny Mahlangu, Johannes Oldenburg, Ido Paz‐Priel, Claude Négrier, Markus Niggli, Maria Elisa Mancuso, Christophe Schmitt, Víctor Jiménez‐Yuste, Christine L. Kempton, Christophe Dhalluin, Michael U. Callaghan, Willem Buján, Midori Shima, Joanne I. Adamkewicz, Elina Asikanius, Gallia G. Levy, Rebecca Kruse‐Jarres	503
7	Hodgkin’s Disease in Costa Rica:A Report of 40 Cases Analyzed for Epstein-Barr Virus 1998 ·American Journal of Clinical Pathology ·(unknown), Yuehua Zhou, Sophia Koo, Carlotta A. Glackin, Willem Buján, L. Jeffrey Medeiros	19
8	Subcutaneous tissue involvement by T-cell lymphoma. A report of 2 cases. 1996 ·PubMed ·(unknown), Willem Buján, (unknown), L. Jeffrey Medeiros	22
9	Bone Marrow Transplantation From Genetically HLA-Nonidentical Donors in Children With Fatal Inherited Disorders Excluding Severe Combined Immunodeficiencies: Use of Two Monoclonal Antibodies to Prevent Graft Rejection 1996 ·PEDIATRICS ·Nada Jabado, F Le Deist, A J Cant, (unknown), Anders Fasth, Gareth J. Morgan, Ashok Vellodi, G Hale, Willem Buján, Carolin Thomas, Marina Cavazzana, John Wijdenes, Alain Fischer	39
10	Transplanted sickle‐cell disease patients with autologous bone marrow recovery after graft failure develop increased levels of fetal haemoglobin which corrects disease severity 1995 ·British Journal of Haematology ·Alina Ferster, Francis Corazza, F. Vertongen, Willem Buján, Christine Devalck, Pierre Fondu, Pascale Cochaux, M. Lambermont, (unknown), Eric Sariban	26
11	Long‐term disease‐free survival in a child with refractory metastatic malignant germ cell tumor treated by high‐dose chemotherapy with autologous bone marrow rescues 1994 ·Medical and Pediatric Oncology ·Christine Devalck, (unknown), Alina Ferster, Marc‐Henri De Laet, Willem Buján, (unknown), Eric Sariban	2
12	Effects of recombinant human granulocyte‐colony stimulating factor on neutropenic mice infected with Candida albicans: acceleration of recovery from neutropenia and potentiation of anti‐C. albicans resistance 1994 ·Mycoses ·(unknown), (unknown), C De Vroey, Francis Corazza, Willem Buján, Pierre Fondu	23
13	Complete remission following donor leukocyte infusion in ALL relapsing after haploidentical bone marrow transplantation. 1994 ·PubMed ·Alina Ferster, Willem Buján, (unknown), Christine Devalck, Peter Heimann, Eric Sariban	28
14	Bone marrow transplantation corrects the splenic reticuloendothelial dysfunction in sickle cell anemia 1993 ·Blood ·Alina Ferster, Willem Buján, Francis Corazza, Christine Devalck, Pierre Fondu, (unknown), (unknown), Eric Sariban	46
15	[Granulocytic sarcoma with mediastinal involvement]. 1993 ·PubMed ·(unknown), A Ferster, (unknown), Willem Buján, (unknown), Christine Devalck, Eric Sariban	1
16	Effect of recombinant human granulocyte colony-stimulating factor in reticular dysgenesis [letter; comment] 1993 ·Blood ·Willem Buján, Alina Ferster, Eric Sariban, W Friedrich	7
17	Effect of recombinant human granulocyte colony-stimulating factor in reticular dysgenesis. 1993 ·Blood ·Willem Buján, Alina Ferster, Eric Sariban, W Friedrich	8
18	USE OF RECOMBINANT HUMAN GRANULOCYTE COLONY STIMULATING FACTOR IN RETICULAR DYSGENESIS 1992 ·British Journal of Haematology ·Willem Buján, Alina Ferster, Nadira Azzi, Christine Devalck, (unknown), Eric Sariban	13
19	[Autologous bone marrow graft in solid tumors in childhood]. 1992 ·PubMed ·Christine Devalck, A Ferster, M H De Laet, (unknown), Willem Buján, (unknown), (unknown), (unknown), (unknown), Eric Sariban	1
20	CD71 phenotype and the value of gallium imaging in lymphomas 1991 ·American Journal of Hematology ·Walter Feremans, Willem Buján, Pierre Nève, Jean‐Pierre Delville, Liliane Schandené	17

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact